Global Insulin Market: Focus on Insulin Delivery Devices - Market Outlook 2022

  • ID: 4085843
  • Report
  • Region: Global
  • 105 Pages
  • Rockville Research
1 of 5
Worldwide, Diabetes Population Has Been Increasing at an Astounding Rate Every Year

FEATURED COMPANIES

  • Eli Lilly and Company
  • Merck & Co.
  • Novo Nordisk
  • Sanofi Aventis
  • MORE

Diabetes has emerged as one of the largest health emergencies of modern age resulting in life-changing complications. It is a chronic condition occurring as a result of insufficient insulin production or inability to use insulin. Worldwide, diabetes population has been increasing at an astounding rate every year. Insulin is a hormone responsible for regulating blood glucose level as part of metabolism.

Depending on the type of diabetes (type 1 diabetes or type 2 diabetes) insulin therapy is used for replacement of insulin that the body is unable to produce. Insulin is generally administered subcutaneously via various methods such as vial and syringe, insulin pen and continuous subcutaneous insulin infusion (CSII). Insulin pens are one of the most convenient and precise insulin delivery option available in the market.

Growth of the global insulin market is propelled by increasing prevalence diabetes, rise in geriatric population, growing obese population, propagation of diabetes management awareness and government impetus. Major factors restraining growth of the market are high cost of insulin, insurance coverage issue, high competition and stringent regulatory pressure.

The report is segmented on the basis of insulin delivery devices market such as syringes, vials, insulin pumps, etc. Market analysis for these devices is provided for current as well as forecasted period.

Furthermore, insulin therapy market assessment is done across major markets such as Europe, North America and China. In-depth analysis of insulin therapy in aforementioned regions is done on the basis of overall insulin market size and market share by treatment option.

Leading industry players operating in the global insulin therapy market include Novo Nordisk, Sanofi Aventis, Eli Lilly and Company; and Merck & Co. These industry players are profiled herein based on attributes such as business overview, product segments, financial and business strategies. The report also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global insulin therapy market.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eli Lilly and Company
  • Merck & Co.
  • Novo Nordisk
  • Sanofi Aventis
  • MORE

1. Executive Summary

2. Research Methodology

3. Introduction

4. Diabetes
    4.1 Overview
    4.2 Cost - Human & Financial

5. Insulin Market
    5.1 Overview
    5.2 Market Analysis
        5.2.1 Market Sizing (Actual & Forecasted)
        5.2.2 Market Share by Insulin Type
        5.2.3 Market Share by Segment
        5.2.4 Market Share by Region

6. Insulin Delivery Devices
    6.1 Overview
    6.2 Vial and syringe
        6.2.1 Overview
        6.2.2 Market Sizing (Actual & Forecasted)
    6.3 Insulin pen
        6.3.1 Overview
        6.3.2 Market Sizing (Actual & Forecasted)
    6.4 Insulin Pump
        6.4.1 Overview
        6.4.1 Market Sizing (Actual & Forecasted)
    6.5 Others
    6.6 Market Share Analysis
        6.6.1 Market Share by Devices
        6.6.2 Market Share by End-User
        6.6.3 Market Share by Region

7. Regional/Country Analysis
    7.1 Europe
        7.1.1 Overview
        7.1.2 Market Sizing (Actual & Forecasted)
        7.1.3 Market Share
    7.2 North America and Caribbean
        7.2.1 Overview
        7.2.2 Market Sizing (Actual & Forecasted)
        7.2.3 Market Share
    7.3 China
        7.3.1 Overview
        7.3.2 Market Sizing (Actual & Forecasted)
        7.3.3 Market Share

8. Pricing Analysis

9. Global Insulin Market Dynamics
    9.1 Industry Trends & Developments
        9.1.1 Dominance of Modern and New-Generation Insulin
        9.1.2 Advent of  Intelligent Insulin Pens
        9.1.3 Sensor-augmented Pump Therapy
        9.1.4 Approval of Glargine Basaglar - The First “Biosimilar” Insulin in the US
    9.2 Growth Drivers
        9.2.1 Increasing Prevelance of Diabetes
        9.2.2 Rise in Geriatric Population
        9.2.3 Growing Obese Population
        9.2.4 Propogation of Diabetes Management Awareness
        9.2.5 Government Impetus
    9.3 Challenges
        9.3.1 High Cost of Insulin
        9.3.2 Insurance Coverage issue
        9.3.3 High Competition
        9.3.4 Regulatory Pressure

10. Competitive Landscape
    10.1 Market Share by Competitors
    10.2 Market Share by Drug Brands

11. Company Profiles
    11.1 Novo Nordisk
    11.2 Sanofi Aventis
    11.3 Eli Lilly and Company
    11.4 Merck & Co.

List of Tables
Table 1: Insulin and Diabetes Drugs Approved Between 2012-2016
Table 2: Worldwide Sales of Various Types of Insulin, 2015 (US$ Billions)
Table 3: Top Insulin Pump Comparisons
Table 4: Comparison of Insulin Pumps and Insulin Pens
Table 5: Europe Diabetes Statistics
Table 6: North America Diabetes Statistics
Table 7: China Diabetes Statistics
Table 8: Prices of Popular Insulins
Table 9: Proportion of Undiagnosed Diabetic Population Aged (20-79 years), 2015
Table 10: Coverage of Popular Insulin Drug Brands
Table 11: Novo Nordisk - Diabetes R&D Pipeline
Table 12: Sanofi Aventis Diabetes Pipeline
Table 13: Eli Lilly and Company Clinical Development Pipeline
Table 14: Merck & Co. Product Pipeline

List of Figures
Figure 1: Research Methodology
Figure 2: Top ten countries/territories for Number of Adults with Diabetes
Figure 3: Global Diabetes Care Market by Treatment Class, 2011-15 (US$ Millions)
Figure 4: Insulin Production and Action
Figure 5: Global Insulin Market Size by Value, 2011-16E (US$ Billions)
Figure 6: Global Insulin Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 7: Global Insulin Market Share by Type (2015)
Figure 8: Global Insulin Market (Volume) Share by Segment (2016)
Figure 9: Global Insulin Market (Volume) Share by Region (2015)
Figure 10: Global Insulin Syringes Market Size by Value, 2014-22E (US$ Billions)
Figure 11: Global Insulin Pumps Market Size by Value, 2014-22E (US$ Billions)
Figure 12: Global Insulin Pens Market Size by Value, 2014-22E (US$ Billions)
Figure 13: Global Insulin Injectors Market Size by Value, 2014-22E (US$ Billions)
Figure 14: Global Insulin Delivery Devices Market Share by Product, 2014-22E (US$ Million)
Figure 15: Global Insulin Delivery Devices Market Share by End-User, 2016 & 2022E
Figure 16: Insulin Delivery Devices Market Share by Region (2015)
Figure 17: Global Insulin Delivery Devices Market Share by Region, 2016 & 2022E
Figure 18: Europe - Insulin Market Size by Value, 2011-16E (US$ Billions)
Figure 19: Europe - Insulin Market Size by Value Forecasted, 2017E-22E (US$ Billions)
Figure 20: Europe - Insulin Market Share by Insulin Type (2015)
Figure 21: The US - Insulin Market Size by Value, 2011-16E (US$ Billion)
Figure 22: The US - Insulin Market Size by Value Forecasted, 2017E-22E (US$ Billion)
Figure 23: The US - Insulin Market (Volume) Share by TRx, 2011 & 2015
Figure 24: The US - Insulin Market Share by Insulin Type (2015)
Figure 25: China - Insulin Market Size by Value, 2011-16E (US$ Billion)
Figure 26: China - Insulin Market Size by Value Forecasted, 2017E-22E (US$ Billion)
Figure 27: China - Insulin Market Share by Insulin Type (2015)
Figure 28: Worldwide Insulin Price Comparison, Cost per vial of Insulin (Feb’2016)
Figure 29: Worldwide Insulin Cost Increment, 2005 vs. 2015
Figure 30: Cost of Insulin, Jul’1996 - Jul’2016
Figure 31: Intelligent Insulin Pens Connectivity through Different Methods
Figure 32: Worldwide Diabetes Incidence by Region, 2015 & 2040E (Millions)
Figure 33: Prevalence of people with diabetes by age and sex, 2015
Figure 34: Global Obese Population, 2000-2016
Figure 35: Global Diabetes Care Market (Value) Share by Competitors (2016)
Figure 36: Global Modern Insulin Volume Market Share by Competitors (2016)
Figure 37: Global Insulin Unit Share by Drug Brands (2016)
Figure 38: Global Basal Insulin Market Share by Drug Brands (2015)
Figure 39: Global Rapid-Action Insulin Market Share by Drug Brands (2015)
Figure 40: Novo Nordisk Diabetes and Obesity Care Sales by Segment, FY2012-FY2016 (US$ Billion)
Figure 41: Sanofi Aventis Net Sales, FY2012-FY2016 (US$ Billion)
Figure 42: Merck & Co. Revenue by Business Segment (FY2016)
Figure 43: Merck & Co. Net Sales, FY2012-FY2016 (US$ Billion)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Eli Lilly and Company
  • Merck & Co.
  • Novo Nordisk
  • Sanofi Aventis
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll